Platinum-based Drugs Market, By Type (Cisplatin, Oxaliplatin, Carboplatin, and Other), By Application (Colorectal Cancer, Ovarian Cancer, Lung Cancer, and Other), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2029

Report Code: PMI430820 | Publish Date: May 2023 | No. of Pages: 144

Global Platinum Based Drugs Market Overview

Platinum-based drugs comprise organized complexes of platinum. They are chemotherapeutic agents, mainly utilized in the treatment of cancer. Platinum witnesses as cell damaging agent for some cancer treatments. About 10% to 20% patients treated with chemotherapy receive platinum-based drugs. These drugs are used either alone or in combination with other drug treatment. The Global Platinum-based Drugs Market accounted for US$ 1473.95 million in 2020 and is estimated to be US$ 2245.91 million by 2030 and is anticipated to register a CAGR of 4.3%.

Global Platinum Based Drugs Market Dynamics

Growth in prevalence of cancer

Increasing incidence of cancer is a major driving factor of the global platinum-based drugs market. As per National Cancer Institute report, the number of new cancer cases per year is projected to increase to 23.6 million by 2030. Platinum based cancer drugs market involves recent developments such as development of analog platinum drugs including platinum carrier molecule complexes to boost targeted concentration of drugs in cancer tumor. According to the WHO report, cancer is the second dominating cause of death worldwide, and estimates for an approximately 9.6 million deaths in 2018, including lung cancer estimating for 2.09 million cases.

Conversely, drug-related side effects and resistance growth are the major limitations of this industry worldwide.

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Global Platinum Based Drugs Market Segmentation

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

The global platinum-based drugs market is segmented based on type, application, and region.

On the basis of type, the global platinum-based drugs market is segmented into cisplatin, oxaliplatin, carboplatin, and other. On the basis of application, the target market is classified into colorectal cancer, ovarian cancer, lung cancer, and other.

Regional Insights:

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

On region the global platinum-based drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America leads the global market in 2018 owing to growing incidence of cancer in the region, expansions in platinum-based drugs, and recent FDA approvals. Asia Pacific market is expand to grow at the highest CAGR due to rise in prevalence of diseases, increase in per capita income, improvement in health care infrastructure, and surge in awareness.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Attribute

Details

Base year for estimation

2020

Forecast period

2020 – 2029

Market representation

Revenue in USD Million & CAGR from 2020 – 2029

Market Segmentation

By Type - Cisplatin, Oxaliplatin, Carboplatin, and Other

By Application - Colorectal Cancer, Ovarian Cancer, Lung Cancer, and Other

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest application trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the global platinum-based drugs market report based on type, application, and region.

Global Platinum-based Drugs Market, By Type:

  • Cisplatin
  • Oxaliplatin
  • Carboplatin
  • Other

Global Platinum-based Drugs Market, By Application:

  • Colorectal Cancer
  • Ovarian Cancer
  • Lung Cancer
  • Other

Global Platinum-based Drugs Market, By Region:

      • North America
          • U.S.
          • Canada
      • Europe
          • Germany
          • UK
          • France
          • Russia
          • Italy
          • Rest of Europe
      • Asia Pacific
          • China
          • India
          • Japan
          • South Korea
          • Rest of Asia Pacific
      • Latin America
          • Brazil
          • Mexico
          • Rest of Latin America
      • Middle East & Africa
          • GCC
          • Israel
          • South Africa
          • Rest of Middle East & Africa

Global Platinum Based Drugs Market Key Players

The key players operating the global platinum-based drugs market includes Pfizer, Inc., Ask-Pharma, Mylan N.V., Sanofi, Sun Pharmaceutical Industries Ltd., Accord Healthcare, Guizhou YiBai Pharmaceutical Co., Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., and Qilu Pharmaceutical Co., Ltd. Prominent key players are constantly involved in depending new treatment options to treat various diseases in order to provide safe and effective treatments for the patients. For instance, in February 2017, EMD Serono of Merck KGaA, Darmstadt, Germany, in the US and Canada, and Pfizer Inc. declared the US Food and Drug Administration (FDA) approval of Biologics License Application (BLA) for avelumab. Avelumab is used for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) with disease progression on or after platinum-based therapy.

Global Platinum Based Drugs Market Company Profile

  • Pfizer, Inc.
    • Company Overview
    • Product Type Portfolio
    • Key Highlights
    • Financial PerRaw Materialance
    • Business Strategies
  • Ask-Pharma
  • Mylan N.V.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Accord Healthcare
  • Guizhou YiBai Pharmaceutical Co., Ltd.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Qilu Pharmaceutical Co., Ltd.

“*” marked represents similar segmentation in other categories in the respective section

Global Platinum Based Drugs Market Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for Platinum-based Drugs Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Type
      • Market Snippet, By Application
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Global Platinum-based Drugs Market, By Type, 2020 – 2029, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2029
      • Y-o-Y Growth Analysis (%), 2020 – 2029
      • Segment Trends
    • Cisplatin
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Oxaliplatin
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Carboplatin
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
  6. Global Platinum-based Drugs Market, By Application, 2020 – 2029, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2029
      • Y-o-Y Growth Analysis (%), 2020 – 2029
      • Segment Trends
    • Colorectal Cancer
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Ovarian Cancer
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Lung Cancer
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
  7. Global Platinum-based Drugs Market, By Region, 2020 – 2029, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2029
      • Y-o-Y Growth Analysis (%), 2020 – 2029
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2029
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2029
        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2029
        • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2029
      • Market Size  and Forecast (US$ Mn), By Country, 2020 – 2029
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2029
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  9. Company Profiles
      • Pfizer, Inc.
        • Company Overview
        • Type Portfolio
        • Key Highlights
        • Financial Overview
        • Business Strategies
      • Ask-Pharma
      • Mylan N.V.
      • Sanofi
      • Sun Pharmaceutical Industries Ltd.
      • Accord Healthcare
      • Guizhou YiBai Pharmaceutical Co., Ltd.
      • Novartis AG
      • Teva Pharmaceutical Industries Ltd.
      • Qilu Pharmaceutical Co., Ltd.
  10. The Last Word
    • Future Impact
    • About Us
    • Contact

FAQs

The global platinum-based drugs market is segmented based on type, application, and region.

Increasing the incidence of cancer is a major driving factor of the global platinum-based drug market.

North America leads the global market in 2018 owing to the growing incidence of cancer in the region, expansions in platinum-based drugs, and recent FDA approvals.

Prominent key players are constantly involved in depending on new treatment options to treat various diseases in order to provide safe and effective treatments for the patients. For instance, in February 2017, EMD Serono of Merck KGaA, Darmstadt, Germany, in the US and Canada, and Pfizer Inc. declared the US Food and Drug Administration (FDA) approval of Biologics License Application (BLA) for avelumab.